Prevalence of HR-HPV subtypes tested by Cytopathology
Research type
Research Study
Full title
Analysis of the prevalence of High Risk-Human Papilloma Virus (HR-HPV) subtypes of women referred to different colposcopy clinics by the Cytopathology department of Frontier Pathology
IRAS ID
198455
Contact name
Deborah Carmichael
Contact email
Sponsor organisation
Brighton and Sussex Hospitals NHS Trust
Duration of Study in the UK
0 years, 4 months, 1 days
Research summary
This study will be carried out in the Cytology department, which is part of Frontier Pathology at the Royal Sussex County Hospital, Brighton. The research question addressed is the prevalence of different High Risk-Human Papilloma Virus (HR-HPV) subtypes in the local population. HR-HPV causes cervical cancer in women, and there is now a vaccine given to girls to protect against the 2 most common HR-HPV types. These vaccinated girls have not yet entered the NHSCSP and so the vaccination should not impact at all on the study. It is an important study, as different HR-HPV types in the population might make the vaccine less effective than expected as the HR-HPV subtypes people are infected with may not be the common ones. The data will be gathered on women who are aged 25-64 and have had a positive HR-HPV test when their cervical smear was tested. These women will have been routinely referred to, as part of the NHSCSP, a colposcopy clinic at either Worthing; Chichester; Southlands, Shoreham-by-sea; Royal Sussex County Hospital, Brighton; Princess Royal Hospital, Haywards Heath; Crawley; Dorking; Eastbourne; or Hastings, depending on where they live. This referral is standard practice as part of the NHSCSP and data is transferred securely to these sites. A minimum of 1737 women, with a minimum sample size of 193 per colposcopy clinic will be included in order to carry out a statistically significant investigation. The study will last approximately 6 months, but all data will be gathered from information already at the laboratory so no new tests will be carried out on the women. If there is a significant difference for HR-HPV subtypes between population then this could impact on the future of cervical screening programmes, as well as indicate the likely outcome when screening a vaccinated population.
REC name
N/A
REC reference
N/A